Cancer Prevention Clinical Trials Network (CP-CTNet)

A medical professional shakes hands with a patient seated on a examination table.

The Cancer Prevention Clinical Trials Network (CP-CTNet) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions. By conducting prevention studies on people at increased risk due to inherited conditions, certain conditions that are associated with developing cancer, lifestyle-related risk or environmental exposure, the hope is to develop safe drugs and approaches that can decrease the risk of cancer.

These interventions target molecules or processes known to be important during carcinogenesis, such as cell proliferation (growth), apoptosis (programmed cell death), growth factor expression, oncogene expression, and immune response. The data from these trials help to develop further scientific insights into the mechanisms of cancer prevention, including the development of novel potential markers of response.

CP-CTNet trials are carried out across the United States and include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical. The overall goal of the network is to identify safe and effective preventive interventions that can move into large-scale clinical trials. See a list of trials.

Funding Opportunities and Application Information 2024

No matching Funding Opportunities were found.

View All Funding Opportunities

Grantee Details

PI Name	PI Organization	Title Sort descending	Grant Number	Program Official
Temprosa, Marinella	George Washington University United States	22/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) – Biostatistics Center	2U01DK048489-28	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Goel, Ajay	Beckman Research Institute/City Of Hope United States	5mC and 5hmC DNA alterations as sensitive and specific biomarkers for the non-invasive early detection of pancreatic ductal adenocarcinoma	1U01CA296639-01A1	Claire Zhu, Ph.D.
Reb, Anne	Beckman Research Institute/City Of Hope United States	A Blended e-Health Intervention for Fear of Progression in Advanced GYN Cancer	1R21CA293326-01	Brennan Streck, Ph.D., RN, M.P.H.
Reb, Anne	Beckman Research Institute/City Of Hope United States	A Blended e-Health Intervention for Fear of Progression in Advanced GYN Cancer	1R21CA293326-01	Brennan Streck, Ph.D., RN, M.P.H.
Markowitz, Sanford D.	Case Western Reserve University United States	A Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett's Esophagus and Its Progression	1R01CA295877-01
Pfleger, Cathie M	Icahn School Of Medicine At Mount Sinai United States	A Drosophila model for Aromatase Inhibitor-induced Musculoskeletal Pain	1R21CA303409-01	Rachel Altshuler, Ph.D.
Pfleger, Cathie M	Icahn School Of Medicine At Mount Sinai United States	A Drosophila model for Aromatase Inhibitor-induced Musculoskeletal Pain	1R21CA303409-01	Rachel Altshuler, Ph.D.
Kanetsky, Peter A	H. Lee Moffitt Cancer Ctr & Res Inst United States	A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers	5R01CA291735-02	Claire Zhu, Ph.D.
Wang, Tza-Huei Jeff	Johns Hopkins University United States	A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies	5R33CA272321-03	Christos Patriotis, Ph.D., M.Sc.
Li, Chi	University Of Louisville United States	A lung cancer vaccine based on exosomes of induced pluripotent stem cells	1R21CA280453-01	John Clifford, Ph.D.
Diaz, Juan Sebastian Gomez	University Of California At Davis United States	A miniaturized neural network enabled nanoplasmonic spectroscopy platform for label-free cancer detection in biofluids	3R01CA273253-03S1	Nicholas Hodges, Ph.D.
Somers, Tamara J	Duke University United States	A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial	5R01CA237892-05	Brennan Streck, Ph.D., RN, M.P.H.
Somers, Tamara J	Duke University United States	A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial	5R01CA237892-05	Brennan Streck, Ph.D., RN, M.P.H.
Wang, Hsiao-Lan	University Of Alabama At Birmingham United States	A Motion Exergaming Approach to Promote Self-Managing Fatigue and Pain after Head and Neck Cancer Treatment	5R01CA244947-06	Goli Samimi, Ph.D., M.P.H.
Wang, Hsiao-Lan	University Of Alabama At Birmingham United States	A Motion Exergaming Approach to Promote Self-Managing Fatigue and Pain after Head and Neck Cancer Treatment	5R01CA244947-06	Goli Samimi, Ph.D., M.P.H.

1
2
3
4
…
Next page
Last page

Program Guidelines for CP-CTNet

The Program Guidelines are available as a PDF.

Important Links

Clinical Trial Management Information can be found at CP-CTNet Instructions, Forms and Templates.

The data and biospecimens from several early phase prevention studies are available for request from the Cancer Data Access System (CDAS).

The link to the DMACC website can be found here: Data Management, Auditing and Coordinating Center (DMACC).

Downloadable files

Newsletters

The CP-CTNet Newsletter shares programmatic and research updates for the Cancer Prevention Clinical Trials Network (CP-CTNet). See the latest and all previous issues on the DMACC website.

I-SCORE Meetings

The Investigators-Site Coordinators Opportunity for Research Excellence (I-SCORE) meetings are held annually to stimulate information sharing and collaborations among DCP staff and Consortia members and to develop strategies to scientifically and operationally enhance DCP’s research program.

2025 I-SCORE will be held March 27-28, 2025 at NCI Shady Grove. For more information visit https://events.cancer.gov/dcp/iscore.

How Investigators Can Use CP-CTNet to Conduct Their Own Research

Accruing adequate numbers of study participants is a persistent challenge, especially for independent researchers. CP-CTNet, a cancer prevention research cooperative agreement-funded network, can provide a rich resource of individuals at risk for cancer who may be interested in participating in clinical trials.

An investigator interested in conducting a clinical trial with an agent ready for clinical testing can join a Lead Academic Organization to become an Affiliated Organization
An investigator who wishes to provide an agent for clinical study (but not to perform the clinical trial) can discuss with NCI/DCP if the agent is appropriate for study in CP-CTNet and then enter into a formal agreement with NCI/DCP to allow CP-CTNet to perform the trial
An investigator with a potential agent that requires more efficacy assessment or toxicology studies before moving to a clinical trial can be directed to the NCI/DCP PREVENT Cancer Preclinical Drug Development Program (PREVENT)

NCI/DCP has developed guidelines and processes to assist investigators in accessing CP-CTNet.

The CP-CTNet funding supports the Lead Academic Organizations (LAO) and the organizations affiliated with the LAO Sites. These funds are directed to the management and oversight of clinical trials, trial conduct, participant care as well as primary and major secondary endpoint analyses. Additional outside funds, such as those from institutional, foundation, or other grant programs may be utilized.

For more information, contact Goli Samimi, Ph.D., M.P.H., CP-CTNet Director, at goli.samimi@nih.gov.